<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361034</url>
  </required_header>
  <id_info>
    <org_study_id>GRC 27864-102</org_study_id>
    <secondary_id>2014-001932-13</secondary_id>
    <nct_id>NCT02361034</nct_id>
  </id_info>
  <brief_title>To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects</brief_title>
  <official_title>A Two-Part, Phase I Study of Orally Administered GRC 27864, a Novel, Microsomal Prostaglandin E Synthase-1 Enzyme (mPGES-1) Inhibitor, to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses in Healthy Subjects (Part 1), and of Multiple Doses in Elderly Subjects (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Pharmaceuticals S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multiple Ascending dose (MAD) study with GRC 27864 in Healthy and Elderly Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of TEAEs and serious adverse events (SAEs) after multiple oral doses of GRC 27864 in healthy adult and elderly subjects</measure>
    <time_frame>Baseline upto 42 days after administration of the study drug.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of GRC 27864 and its metabolite GRC 27884 following multiple doses in healthy adult subjects and elderly subjects.</measure>
    <time_frame>Predose and postdose from 0.25 to 48 hrs and from Day 1 to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of GRC 27864 and its metabolite GRC 27884 following multiple doses in healthy adult subjects and elderly subjects.</measure>
    <time_frame>Predose and postdose from 0.25 to 48 hrs and from Day 1 to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve [AUC0-t and AUC0-tau] of GRC 27864 and its metabolite GRC 27884 following multiple doses in healthy adult subjects and elderly subjects.</measure>
    <time_frame>Predose and postdose from 0.25 to 48 hrs and from Day 1 to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t½) of GRC 27864 and its metabolite GRC 27884 following multiple doses in healthy adult subjects and elderly subjects.</measure>
    <time_frame>Predose and postdose from 0.25 to 48 hrs and from Day 1 to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (V)/bioavailability (F) of GRC 27864 and its metabolite GRC 27884 following multiple doses in healthy adult subjects and elderly subjects.</measure>
    <time_frame>Predose and postdose from 0.25 to 48 hrs and from Day 1 to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)/F of GRC 27864 and its metabolite GRC 27884 following multiple doses in healthy adult subjects and elderly subjects.</measure>
    <time_frame>Predose and postdose from 0.25 to 48 hrs and from Day 1 to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed accumulation ratio (Rac) of GRC 27864 and its metabolite GRC 27884 following multiple doses in healthy adult subjects and elderly subjects.</measure>
    <time_frame>Predose and postdose from 0.25 to 48 hrs and from Day 1 to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid (CSF) concentrations of GRC 27864 and its metabolite GRC 27884 (CmaxCSF) following multiple doses to healthy adult subjects</measure>
    <time_frame>6 hours, and 24 hours postdose on Day 26</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GRC 27864</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test treatment GRC 27864</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRC 27864</intervention_name>
    <arm_group_label>GRC 27864</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects, aged ≥18 to &lt;55 years (&gt; 65 years for elderly cohort) at the
             time of informed consent

          2. Body mass index (BMI) within the range 18.5-32 kg/m2 (inclusive); weight must be &gt;50
             kg

          3. Subjects who are healthy and free from clinically significant illness or disease

          4. Females must be of non-childbearing potential, surgically sterile.

          5. Male subjects whose partners are of childbearing potential or have undergone tubal
             ligation must agree to use 2 highly effective methods of contraception

        Exclusion Criteria:

          1. Systolic blood pressure (SBP) &lt;90 mmHg or &gt;140 mmHg, diastolic blood pressure (DBP)
             &lt;45 mmHg or &gt;90 mmHg, resting pulse rate &lt;40 beats per minute (bpm) or &gt;100 bpm

          2. Subjects who have the presence of active peptic ulcer disease, gastrointestinal (GI)
             bleeding, chronic gastritis, inflammatory bowel disease, chronic diarrhoea or positive
             13C urea breath/faecal test for Helicobacter pylori at Screening.

          3. Subjects with inherited or acquired disorders of platelet function, bleeding or
             coagulation.

          4. Presence of any clinically relevant acute or chronic disease that could interfere with
             the subject's safety during the clinical study, expose the subject to undue risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Bush, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Ltd</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety and pharmacokinetics of drug in healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

